Dermatan disulfate, an inhibitor of thrombin generation and activation
US5922690A · kind A · utility
21Cited by
7References
46Claims
0Family size
Inventors
Key dates
| Filing date | Feb 6, 1997 |
| Grant date | Jul 13, 1999 |
| Priority date | — |
| Expiry date | Feb 6, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC08B37/0069
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of inhibiting thrombin generation and of inhibiting complement activation by using a dermatan sulfate having at least 2 sulfate groups per disaccharide obtained by chemical sulfation of native dermatan sulfate. The resulting dermatan sulfate having an average molecular weight from about 5000 to 35000 Daltons is characterized by (i) a high content of L-iduronic->4,6-di-O-sulfated N-acetyl-D-galactosamine residues, and (ii) a specific heparin cofactor II-mediated anti-thrombin activity, depending on average molecular weight, between about 25 to 125 U/mg.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.